<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04386343</url>
  </required_header>
  <id_info>
    <org_study_id>CH1701</org_study_id>
    <nct_id>NCT04386343</nct_id>
  </id_info>
  <brief_title>CH1701 for Prevention and Treatment of Radiation Burns</brief_title>
  <acronym>CH1701</acronym>
  <official_title>A Combined Phase I&amp;II, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety for Prevention and Treatment of Radiation Therapy Burn of CH1701</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vietlife Healthcare Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vietnam National Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vietlife Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A combined Phase I&amp;II, randomized, double-blind, placebo-controlled clinical trial to
      evaluate efficacy and safety for prevention and treatment of radiation therapy burn of CH1701
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 5, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase I: Three dose level - 50%, 100% and 167% of the expected dose level Phase II: Four dose level - 0% (Placebo), 50%, 100% and 167% of the expected dose level</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Participants and investigator are blinded to the treatment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Side effects by skin biopsy</measure>
    <time_frame>14 days</time_frame>
    <description>Skin biopsy after 14 days of topical application, compared with healthy skin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Degree of burns according to CTCAE 4.03 atlas</measure>
    <time_frame>63 days</time_frame>
    <description>Take photograph of skin every week comparing with atlas CTCAE 4.03 to determine the degree of burns</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>50% dose level arm - Phase I</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 healthy volunteer will use 50% dose level for Phase I in the left hand side and use placebo in the right hand side</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100% dose level arm - Phase I</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 healthy volunteer will use 100% dose level for Phase I in the left hand side and use placebo in the right hand side</description>
  </arm_group>
  <arm_group>
    <arm_group_label>167% dose level arm - Phase I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 healthy volunteer will use 167% dose level for Phase I in the left hand side and use placebo in the right hand side</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm - Phase II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 Breast cancer patients will use Placebo in the radiation affected area right after radiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50% dose level arm - Phase II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 Breast cancer patients will use CH1701 with 50% of the expected dose level in the radiation affected area right after radiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100% dose level arm - Phase II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 Breast cancer patients will use CH1701 with 100% of the expected dose level in the radiation affected area right after radiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>167% dose level arm - Phase II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 Breast cancer patients will use CH1701 with 167% of the expected dose level in the radiation affected area right after radiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CH1701 for prevention and treatment of radiation burns.</intervention_name>
    <description>Ch1701 is used for cancer patients who are treated with radiotherapy, then assess the safety and treatment effectiveness of the product.</description>
    <arm_group_label>100% dose level arm - Phase II</arm_group_label>
    <arm_group_label>167% dose level arm - Phase II</arm_group_label>
    <arm_group_label>50% dose level arm - Phase II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Safety assessment of CH1701</intervention_name>
    <description>Safety assessment of CH1701 after 14 days of use on volunteers</description>
    <arm_group_label>100% dose level arm - Phase I</arm_group_label>
    <arm_group_label>167% dose level arm - Phase I</arm_group_label>
    <arm_group_label>50% dose level arm - Phase I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>The placebo was used on patients as a control for the doses of CH1701</description>
    <arm_group_label>Placebo arm - Phase II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        *Phase I:

        Inclusion Criteria:

          -  Healthy volunteers, aged 18 and older at the time of enrollment

          -  Voluntarily participate in the study by signing a consent form to participate in the
             study

          -  Ability to adhere to treatment according to researchers' assessment

        Exclusion Criteria:

          -  Subjects with other acute or chronic diseases need to be treated

          -  It is not possible to comply with the research or studied drug treatment process in
             the opinion of the researcher

               -  Phase II:

        Inclusion Criteria:

          -  Female patient, aged 18 to 60 years old

          -  Having been diagnosed with breast cancer with axillary lymph node metastasis, having
             radiation therapy for radiation therapy in the range of 45-50 Gy for a period of 5-6
             weeks

          -  Treatment can be started within 3 days of signing the consent to participate in the
             study

          -  Agree to voluntarily sign the consent form to participate in the study

        Exclusion Criteria:

          -  The available skin lesions in the breast and chest and according to the researchers'
             judgment will affect the assessment of inflammation caused by radiation

          -  The patient had radiation therapy before the breast area

          -  History of connective tissue disorders

          -  The patient is incapable of complying with the research procedures or is unable to
             ensure compliance with the study medication as assessed by the researcher

          -  Participate in other clinical trial studies within 1 month before joining this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vietlife Healthcare Corporation</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 25, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

